Welcome to our dedicated page for Mirum Pharmaceuticals SEC filings (Ticker: MIRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial readouts, orphan-drug exclusivity clauses, and IBAT-inhibitor safety tables can bury the numbers investors need. For Mirum Pharmaceuticals, whose focus on rare cholestatic liver diseases packs every report with dense science, the challenge is even greater. If you have ever searched “Mirum Pharmaceuticals SEC filings explained simply,” you know how quickly a 300-page document can stall your research.
Stock Titan solves that problem. Our AI reviews each Mirum Pharmaceuticals quarterly earnings report 10-Q filing, flags R&D burn, and delivers concise Mirum Pharmaceuticals earnings report filing analysis. Real-time alerts surface Mirum Pharmaceuticals Form 4 insider transactions real-time, letting you track Mirum Pharmaceuticals executive stock transactions Form 4 ahead of pivotal data releases. Need leadership-pay details? The Mirum Pharmaceuticals proxy statement executive compensation section lands in plain English. Even Mirum Pharmaceuticals 8-K material events explained arrive minutes after they hit EDGAR.
Everything is here—from the Mirum Pharmaceuticals annual report 10-K simplified to day-to-day Mirum Pharmaceuticals insider trading Form 4 transactions—all enhanced by understanding Mirum Pharmaceuticals SEC documents with AI. Real-time updates, expert commentary, and a clean interface let professionals compare segment trends, monitor drug-approval milestones, and spot market-moving disclosures without wading through biotech jargon.
Mirum Pharmaceuticals, Inc. (MIRM) – Form 4 insider transaction filing. SVP & Global Controller Jolanda Howe reported three transactions between 1–3 July 2025.
- 1 Jul 2025: 1,041 restricted stock units (RSUs) converted into an equal number of common shares (Transaction Code M). Post-conversion ownership temporarily rose to 3,467 shares.
- 2 Jul 2025: 564 shares sold at $48.25 (Code S) to cover tax-withholding obligations tied to the RSU vesting.
- 3 Jul 2025: 477 shares sold at $49.08 under a pre-existing Rule 10b5-1 plan adopted 16 Dec 2024.
Following these actions, Howe’s direct beneficial ownership declined from 3,467 to 2,426 common shares. All 1,041 RSUs from the reported award are now fully settled, leaving no outstanding derivative securities.
The RSU grant vests in three equal annual installments that began on 1 Jul 2023. All reported transactions were executed by a single insider; no joint filings were made.
This Form 144 filing discloses that an insider of Jabil Inc. (JBL) intends to sell 1,000 common shares through UBS Financial Services on or about 07 / 03 / 2025. The estimated aggregate market value of the proposed sale is $222,750, implying a reference price of roughly $222.75 per share. Jabil has 107,345,348 shares outstanding, so the planned disposition represents approximately 0.0009 % of total shares—a de-minimis amount for the company and its float.
The filer previously sold 2,500 shares on 06 / 20 / 2025 for gross proceeds of $518,933. The shares being sold were originally acquired as restricted stock units (RSUs) on 10 / 20 / 2023. No adverse, non-public information is asserted by the filer, and there is no indication of a material change in Jabil’s operations or outlook. Overall, the notice signals routine insider portfolio diversification rather than a strategic or financial shift for the company.
FAQ
What is the current stock price of Mirum Pharmaceuticals (MIRM)?
What is the market cap of Mirum Pharmaceuticals (MIRM)?
What is the core focus of Mirum Pharmaceuticals?
What therapeutic areas does the company target?
How does Mirum Pharmaceuticals differentiate its products?
What type of products are in the company’s pipeline?
Where is Mirum Pharmaceuticals headquartered and when was it founded?
How does the company generate revenue?
Who are the likely competitors for Mirum Pharmaceuticals?
What makes the company’s approach to drug development unique?
